Genetic testing of early breast tumours could allow patients to go without chemo

Bookmark and Share
Published: 3 Jun 2018
Views: 1476
Rating:
Save
Dr Joseph Sparano - Albert Einstein Cancer Center, New York, USA

Dr Sparano presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from the TAILORx trial.

The results show that 70% of women with early HR / HER2- breast cancer could be spared chemotherapy, based on the results from a 21gene assay.

For more on these results, watch his interview with ecancer and read our news coverage here.

Slides from this presentation are available here.